Pharmacological and clinical profile of pilocarpine hydrochloride (SALAGEN® Tab. 5 mg)

Folia Pharmacologica Japonica

Volumn 127, Issue 5, 2006, Pages 399-407

  Maruyama, Kazuyasu ^a   Koshihara, Naomi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; OTENZEPAD; PILOCARPINE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR;

DRUG ACTIVITY; IC 50; MEDICAL RESEARCH; MOLECULAR GENETICS; PILOCARPUS; QUALITY OF LIFE; REVIEW; TABLET; VISUAL ANALOG SCALE; ANIMAL; DRUG EFFECT; HUMAN; RADIOTHERAPY; SALIVA; SECRETION; XEROSTOMIA;

ANIMALS; HUMANS; MUSCARINIC AGONISTS; PILOCARPINE; RADIOTHERAPY; RECEPTORS, MUSCARINIC; SALIVA; XEROSTOMIA;

EID: 33747196976     PISSN: 00155691     EISSN: 13478397     Source Type: Journal    
DOI: 10.1254/fpj.127.399     Document Type: Review

References (27)

1. Baum BJ. Biology of the salivary glands: Neurotransmitter control of calcium mobilization. CRC press; 1993. p. 153-180.
2. Baum BJ. Principles of saliva secretion. Ann N Y Acad Sci. 1993;694:17-23.
3. Japanese source
4. Japanese source
5. Eisbruch A, et al. Int J Radiation Oncology Biol Phys. 1996;36:469480.
6. Japanese source
7. Japanese source
8. Japanese source
9. Wynn RL. Gen Dent. 1996;26:29-30.
10. Fox PC, et al. Oral Surg Oral Med Oral Path. 1986;61:243-248.
11. Greenspan D, et al. Cancer. 1987;59:1123-1125.
12. Fox PC, et al. J Dent Res. 1989;68:315.
13. Johnson JT, et al. N Engl J Med. 1993;329:390-395.
14. Leveque FG, et al. J Clin Oncol. 1993;11:1124-1131.
15. Jacobs CD, et al. Oncology. 1996;10 Suppl 3:16-20.
16. Japanese source
17. Japanese source
18. Japanese source
19. Japanese source
20. Japanese source
21. Dhein S, et al. Pharmacol Res. 2001;44:161-182.
22. Watson N, et al. Br J Pharmacol. 1999;127:590-596.
23. Japanese source
24. Japanese source
25. Omori Y, et al. Arzneim Forsch/Drug Res. 2003;53:342-350.
26. Japanese source
27. Japanese source